• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    120.15 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Apr 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,899
    Open 120.15
    Bid (Size) 119.50 (100)
    Ask (Size) 120.99 (100)
    Prev. Close 120.15
    Today's Range 120.15 - 120.15
    52wk Range 73.31 - 125.14
    Shares Outstanding 2,531,374,696
    Dividend Yield 2.83%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
    Via StockStory
    News headline image
    The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
    As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
    Via Finterra
    Topics Earnings Economy Intellectual Property

    Performance

    YTD
    +12.9%
    +12.9%
    1 Month
    +4.1%
    +4.1%
    3 Month
    +10.0%
    +10.0%
    6 Month
    +40.2%
    +40.2%
    1 Year
    +51.8%
    +51.8%

    More News

    Read More
    News headline image
    Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
    From Daiichi Sankyo
    Via Business Wire
    Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗
    Via Chartmill
    News headline image
    1 Momentum Stock on Our Buy List and 2 We Question
    Via StockStory
    News headline image
    Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
    Via MarketMinute
    Topics Bonds
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
    Via Finterra
    Topics Economy World Trade
    News headline image
    Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
    Via Finterra
    Topics Artificial Intelligence Earnings Economy
    News headline image
    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    Via Finterra
    Topics Initial Public Offering
    News headline image
    Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
    Via MarketBeat
    News headline image
    Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 Reason Eli Lilly Stock Is Still a Buy ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 120.15
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 04/13/26 07:00 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 304.14B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 304B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.